{"id":"latanoprost-dorzolamide","safety":{"commonSideEffects":[{"rate":"25-50","effect":"Conjunctival hyperemia"},{"rate":"10-30","effect":"Eye irritation/discomfort"},{"rate":"5-15","effect":"Increased iris pigmentation"},{"rate":"5-10","effect":"Eyelash growth"},{"rate":"10-20","effect":"Bitter taste (dorzolamide component)"},{"rate":"5-10","effect":"Blurred vision"}]},"_chembl":null,"_dailymed":{"setId":"6ba4f0b3-d776-3485-e053-2991aa0abab3","title":"TIM-BRIM-DOR-LAT (TIMOLOL - BRIMONIDINE - DORZOLAMIDE - LATANOPROST) SOLUTION/ DROPS [IMPRIMISRX NJ]"},"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Latanoprost is a prostaglandin F analog that binds to prostaglandin F receptors and enhances drainage of aqueous humor through the uveoscleral pathway. Dorzolamide is a carbonic anhydrase inhibitor that reduces aqueous humor secretion by inhibiting carbonic anhydrase in the ciliary body. Together, these complementary mechanisms provide additive intraocular pressure reduction.","oneSentence":"This combination reduces intraocular pressure by increasing uveoscleral outflow of aqueous humor (latanoprost) and decreasing aqueous humor production (dorzolamide).","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T04:03:16.767Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Open-angle glaucoma"},{"name":"Ocular hypertension"}]},"trialDetails":[{"nctId":"NCT07074782","phase":"","title":"Retinal Ganglion Cell Neuroprotection Under Prostaglandin Analogues","status":"NOT_YET_RECRUITING","sponsor":"Association for Innovation and Biomedical Research on Light and Image","startDate":"2026-01","conditions":"Glaucoma","enrollment":1500},{"nctId":"NCT02390284","phase":"PHASE3","title":"Stop Retinal Ganglion Cell Dysfunction Study","status":"TERMINATED","sponsor":"University of Miami","startDate":"2015-09","conditions":"Glaucoma","enrollment":28},{"nctId":"NCT06883123","phase":"PHASE4","title":"Efficacy of Simbrinza and Rocklatan vs Cosopt and Latanoprost","status":"RECRUITING","sponsor":"Prairie Eye Center","startDate":"2025-05-14","conditions":"Open Angle Glaucoma","enrollment":70},{"nctId":"NCT06369077","phase":"PHASE4","title":"How Much Does Reduced Dosing of Latanoprost and Dorzolamide-timolol Affect Pressure?","status":"TERMINATED","sponsor":"CT Glaucoma Associates","startDate":"2024-04-22","conditions":"Glaucoma, Open-Angle, Glaucoma; Drugs","enrollment":36},{"nctId":"NCT04702789","phase":"PHASE4","title":"Comparative Study of the Efficacy of Either Krytantek Ofteno PF® or Eliptic Ofteno PF® Plus Gaap Ofteno PF® for POAG or Ocular Hypertension.","status":"TERMINATED","sponsor":"Laboratorios Sophia S.A de C.V.","startDate":"2021-10-19","conditions":"Glaucoma, Open-Angle, Ocular Hypertension","enrollment":28},{"nctId":"NCT00572936","phase":"PHASE2","title":"Circadian Rhythms of Aqueous Humor Dynamics in Humans","status":"COMPLETED","sponsor":"University of Nebraska","startDate":"2006-03-13","conditions":"Glaucoma","enrollment":30},{"nctId":"NCT00140049","phase":"PHASE4","title":"A 12week, Randomized, Evaluator-Masked, Parallel Group Comparing Evening Dosing Of Xalacom Vs Cosopt In Subj W/ Glaucoma","status":"COMPLETED","sponsor":"Pfizer's Upjohn has merged with Mylan to form Viatris Inc.","startDate":"2005-07","conditions":"Glaucoma, Open Angle, Ocular Hypertension","enrollment":238},{"nctId":"NCT00397241","phase":"PHASE4","title":"24-hour Study of Dorzolamide/Timolol and Latanoprost/Timolol Fixed Combinations","status":"COMPLETED","sponsor":"Aristotle University Of Thessaloniki","startDate":"2006-09","conditions":"Open-angle Glaucoma","enrollment":33},{"nctId":"NCT02802137","phase":"PHASE4","title":"24-hour Efficacy and Ocular Surface With Talfuprost and Triple Combined Therapy","status":"COMPLETED","sponsor":"Aristotle University Of Thessaloniki","startDate":"2015-03","conditions":"Glaucoma, Ocular Surface Disease","enrollment":43},{"nctId":"NCT04448223","phase":"PHASE2","title":"A Clinical Study to Evaluate the Efficacy and Safety of CKD-351","status":"UNKNOWN","sponsor":"Chong Kun Dang Pharmaceutical","startDate":"2020-06-11","conditions":"Primary Open Angle Glaucoma, Ocular Hypertension","enrollment":100},{"nctId":"NCT01527682","phase":"PHASE2","title":"Efficacy and Safety of Topically Applied Medical Therapy for the Treatment of Pediatric Glaucoma","status":"COMPLETED","sponsor":"Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia","startDate":"2009-07","conditions":"Childhood Glaucoma","enrollment":37},{"nctId":"NCT03966560","phase":"PHASE4","title":"Choroidal Thickness and Its Correlations With Ocular Parameters in Primary Open-angle Glaucoma","status":"COMPLETED","sponsor":"Afyon Kocatepe University Hospital","startDate":"2014-01","conditions":"Glaucoma, Open-Angle","enrollment":96},{"nctId":"NCT01535768","phase":"PHASE4","title":"Effect of Prophylactic Aqueous Suppression on Hyperencapsulation of Ahmed Glaucoma Valves","status":"UNKNOWN","sponsor":"Credit Valley EyeCare","startDate":"2012-02","conditions":"Glaucoma","enrollment":150},{"nctId":"NCT00906594","phase":"PHASE4","title":"Additive Intra-ocular Pressure Reduction Effect of Fixed Combination of Maleate Timolol 0.5%/Dorzolamide 2% on Monotherapy With Latanoprost in Patients With Elevated Intra-ocular Pressure","status":"COMPLETED","sponsor":"University of Sao Paulo","startDate":"2007-09","conditions":"Glaucoma","enrollment":56},{"nctId":"NCT02522039","phase":"NA","title":"Pupillary Response After Glaucoma Medication","status":"COMPLETED","sponsor":"Glostrup University Hospital, Copenhagen","startDate":"2014-05","conditions":"Drug Effect (Glaucoma Drugs)","enrollment":21},{"nctId":"NCT01175902","phase":"NA","title":"Intraocular Pressure and Ocular Perfusion Pressure of Cosopt in Normal Tension Glaucoma","status":"COMPLETED","sponsor":"The Catholic University of Korea","startDate":"2011-03","conditions":"Normal Tension Glaucoma","enrollment":44},{"nctId":"NCT01896180","phase":"PHASE2","title":"Study to Compare the Safety and Efficacy of ALZ-1101 to Latanoprost in Patients With Intraocular Pressure Inadequately Controlled by Latanoprost","status":"COMPLETED","sponsor":"Alleanza Pharmaceuticals, Inc.","startDate":"2013-07","conditions":"Primary Open Angle Glaucoma, Ocular Hypertension, Elevated Intraocular Pressure","enrollment":63},{"nctId":"NCT01887223","phase":"PHASE2","title":"Transconjunctival Needling Revision Versus Medical Treatment","status":"COMPLETED","sponsor":"University of Sao Paulo General Hospital","startDate":"2010-05","conditions":"Primary Open Angle Glaucoma","enrollment":40},{"nctId":"NCT01655758","phase":"PHASE4","title":"24-hour Control of Intraocular Pressure (IOP) in Ocular Hypertension","status":"COMPLETED","sponsor":"University of Parma","startDate":"2002-01","conditions":"Ocular Hypertension","enrollment":61},{"nctId":"NCT00815373","phase":"NA","title":"The Effects of Cosopt® Vs Xalacom® on Ocular Hemodynamics and Intraocular Pressure (IOP) in Primary Open-angle Glaucoma (POAG)","status":"WITHDRAWN","sponsor":"Meir Medical Center","startDate":"2008-12","conditions":"Open-Angle Glaucoma, Ocular Hypertension","enrollment":""},{"nctId":"NCT01304264","phase":"","title":"Intraocular Pressure, Blood Pressure, Ocular Perfusion and Blood Flow Fluctuations in Glaucoma Patients","status":"COMPLETED","sponsor":"Lithuanian University of Health Sciences","startDate":"2011-03","conditions":"Open Angle Glaucoma","enrollment":35},{"nctId":"NCT00619034","phase":"NA","title":"Pharmacological Intervention in Diabetic Retinopathy","status":"COMPLETED","sponsor":"University of Aarhus","startDate":"2007-09","conditions":"Diabetic Retinopathy","enrollment":87},{"nctId":"NCT00804115","phase":"NA","title":"The International Collaborative Exfoliation Syndrome Treatment Study","status":"UNKNOWN","sponsor":"The New York Eye & Ear Infirmary","startDate":"2000-08","conditions":"Exfoliation Syndrome, Glaucoma, Ocular Hypertension","enrollment":277},{"nctId":"NCT00796198","phase":"PHASE4","title":"Effects of Cosopt on IOP and on Ocular Diastolic Perfusion Pressure","status":"UNKNOWN","sponsor":"University of Turin, Italy","startDate":"2008-12","conditions":"Glaucoma","enrollment":50},{"nctId":"NCT00273481","phase":"PHASE4","title":"Cosopt Versus Xalacom","status":"COMPLETED","sponsor":"Pharmaceutical Research Network","startDate":"2005-09","conditions":"Open-Angle Glaucoma, Ocular Hypertension","enrollment":33},{"nctId":"NCT00348400","phase":"PHASE4","title":"Brimonidine Purite 0.15% Versus Dorzolamide 2% Used as Adjunctive Therapy to Latanoprost","status":"COMPLETED","sponsor":"Innovative Medical","startDate":"","conditions":"Glaucoma","enrollment":""},{"nctId":"NCT00440336","phase":"NA","title":"Comparison of Efficacy of Two Groups of Glaucoma Drops (Xalatan vs.Cosopt) in Reducing Eye Pressure Following Laser (SLT)Treatment in the Management of Glaucoma.","status":"UNKNOWN","sponsor":"Advanced Glaucoma Specialists","startDate":"2006-10","conditions":"Open Angle Glaucoma","enrollment":30},{"nctId":"NCT00273429","phase":"PHASE4","title":"Cosopt Versus Xalatan","status":"COMPLETED","sponsor":"Pharmaceutical Research Network","startDate":"2005-04","conditions":"Open-Angle Glaucoma, Ocular Hypertension","enrollment":""}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":14,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["- Latanoprost, a prostaglandin analogue","- Dorzolamide, a potent inhibitor of carbonic anhydrase II"],"phase":"marketed","status":"active","brandName":"Latanoprost, Dorzolamide","genericName":"Latanoprost, Dorzolamide","companyName":"Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia","companyId":"azienda-socio-sanitaria-territoriale-degli-spedali-civili-di-brescia","modality":"Small molecule","firstApprovalDate":"","aiSummary":"This combination reduces intraocular pressure by increasing uveoscleral outflow of aqueous humor (latanoprost) and decreasing aqueous humor production (dorzolamide). Used for Open-angle glaucoma, Ocular hypertension.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}